Cambridge-based techbio company Qureight has named Rebecca Simmons as its new Chief Operating Officer, strengthening its leadership team as it expands global operations.
Qureight develops AI-powered CT imaging biomarkers and a clinical data management platform aimed at improving the study and treatment of lung and heart diseases. The company said Simmons will oversee operational growth and support initiatives designed to scale its platform across clinical trials.
Rebecca Simmons brings more than two decades of experience in operational leadership. She joins from Riverlane, a quantum computing company, where she was COO and helped grow the organisation from ten to 100 employees over five years. During her tenure, she contributed to closing Series A, B, and C funding rounds that raised over £100 million and secured more than £20 million in government grants and contracts.
Before Riverlane, Simmons co-founded THIS Institute, the Healthcare Improvement Studies Institute, where she established strategic partnerships with NHS stakeholders. She has also served in senior advisory roles at the Danish Diabetes and Endocrine Academy. Her academic background includes a PhD in Epidemiology from the University of Cambridge, an MBA from The Open University, an MSc in Epidemiology from the London School of Hygiene and Tropical Medicine, and a BA in Human Sciences from the University of Oxford.
Muhunthan Thillai, co-founder and CEO of Qureight, said, “Rebecca’s experience, expertise and people-centric leadership approach will be instrumental in supporting the team as we scale the company, accelerating our mission to advance the understanding of lung and heart disease. Her blend of rigorous academic training with commercial acumen made Rebecca the natural choice to lead this next chapter of growth for Qureight. Welcome to the team, Rebecca.”
Dr Simmons said, “Qureight’s pioneering AI-powered CT imaging biomarkers and data management platform is enabling real insights to be drawn from complex and diverse health data, to ultimately deliver real impact for patients. The team is already incredible, with an expert team of clinicians, scientists and machine learning engineers. I’m delighted to join the company and am looking forward to an exciting year.”
Qureight’s platform applies AI to clinical trial data, including CT scan images, physiological measurements, and blood biomarkers. The technology allows pharmaceutical clients to access structured trial data in real time, supports AI-guided image workflows, and enables the creation of synthetic control arms to assess treatment effects. Collaborations with partner hospitals provide access to real-world data that informs machine learning models and accelerates drug development for complex lung and heart conditions.
Interstitial lung diseases, a group of over 200 conditions that cause scarring and damage to lung tissue, are among the areas Qureight focuses on. These include Idiopathic Pulmonary Fibrosis, Sarcoidosis, and Hypersensitivity Pneumonitis. Treatments vary widely and may include steroids, immunosuppressants, antifibrotic therapies, or, in severe cases, lung transplantation.
Bertil Lindmark, Chief Medical Officer at Vicore, commented on the collaboration: “Qureight is becoming a real powerhouse in understanding lung fibrosis and related pathological lung processes. Our collaboration helps us gain key insights regarding patient characteristics and drug effects on fibrosis and lung vasculature, and showing how Buloxibutid works in IPF.”
Qureight continues to advance its AI-driven approach to data curation and imaging analysis, aiming to shorten drug development timelines, reduce diagnostic costs, and improve patient outcomes in lung and heart disease research.
